PE20090981A1 - Moleculas aglutinantes de nogo-a mejoradas y uso farmaceutico de las mismas - Google Patents

Moleculas aglutinantes de nogo-a mejoradas y uso farmaceutico de las mismas

Info

Publication number
PE20090981A1
PE20090981A1 PE2008001859A PE2008001859A PE20090981A1 PE 20090981 A1 PE20090981 A1 PE 20090981A1 PE 2008001859 A PE2008001859 A PE 2008001859A PE 2008001859 A PE2008001859 A PE 2008001859A PE 20090981 A1 PE20090981 A1 PE 20090981A1
Authority
PE
Peru
Prior art keywords
seq
cdr
nogo
improved
refers
Prior art date
Application number
PE2008001859A
Other languages
English (en)
Inventor
Carmen Barske
Stefan Frentzel
Anis Khurso Mir
Martin E Schwab
Allessandra Vitaliti
Original Assignee
Novartis Ag
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39156235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090981(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Univ Zuerich filed Critical Novartis Ag
Publication of PE20090981A1 publication Critical patent/PE20090981A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE REFIERE A UNA MOLECULA AGLUTINANTE TAL COMO UN ANTICUERPO MONOCLONAL QUIMERICO O HUMANIZADO QUE SE AGLUTINA CON EL POLIPEPTIDO NOGO A HUMANO O NIG HUMANO, EN DONDE DICHO ANTICUERPO COMPRENDE: A) UNA CADENA PESADA DE INMUNOGLOBULINA O UN FRAGMENTO DE LA MISMA QUE COMPRENDE i) UN DOMINIO VARIABLE QUE COMPRENDE EN SECUENCIA LAS REGIONES HIPERVARIABLES CDR-H1-6A3 (SEC ID NO: 8), CDR-H2-6A3 (SEC ID NO: 9) Y CDR-H3-6A3 (SEC ID NO: 10); E ii) UNA PARTE CONSTANTE DE LA CADENA PESADA DEL TIPO ?4; Y B) UNA CADENA LIGERA DE INMUNOGLOBULINA O UN FRAGMENTO DE LA MISMA QUE COMPRENDE i) UN DOMINIO VARIABLE QUE COMPRENDE EN SECUENCIA LAS REGIONES HIPERVARIABLES CDR-L1-6A3 (SEC ID NO: 11), CDR-L2-6A3 (SEC ID NO: 12) Y CDR-L3-6A3 (SEC ID NO: 13); E ii) UNA PARTE CONSTANTE DE LA CADENA LIGERA DEL TIPO k. SE REFIERE TAMBIEN A UN POLINUCLEOTIDO QUE CODIFICA DICHA MOLECULA AGLUTINANTE, UN VECTOR DE EXPRESION, UN METODO DE PREPARACION DE DICHA MOLECULA PARA UNA COMPOSICION FARMACEUTICA SIENDO UTIL EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER, ENFERMEDAD DE PARKINSON, ESCLEROSIS AMIOTROFICA LATERAL
PE2008001859A 2007-11-02 2008-10-30 Moleculas aglutinantes de nogo-a mejoradas y uso farmaceutico de las mismas PE20090981A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US174107P 2007-11-02 2007-11-02
EP07119847 2007-11-02

Publications (1)

Publication Number Publication Date
PE20090981A1 true PE20090981A1 (es) 2009-08-13

Family

ID=39156235

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001859A PE20090981A1 (es) 2007-11-02 2008-10-30 Moleculas aglutinantes de nogo-a mejoradas y uso farmaceutico de las mismas

Country Status (31)

Country Link
US (2) US8163285B2 (es)
EP (1) EP2207808B1 (es)
JP (1) JP5698534B2 (es)
KR (1) KR101574814B1 (es)
CN (1) CN101910200B (es)
AR (1) AR072934A1 (es)
AU (1) AU2008317724B2 (es)
BR (1) BRPI0818928B1 (es)
CA (1) CA2704357C (es)
CL (1) CL2008003240A1 (es)
CO (1) CO6270357A2 (es)
CY (1) CY1114345T1 (es)
DK (1) DK2207808T3 (es)
ES (1) ES2425768T3 (es)
HK (1) HK1143597A1 (es)
HR (1) HRP20130699T1 (es)
IL (2) IL205357A (es)
JO (1) JO2876B1 (es)
MA (1) MA31805B1 (es)
MX (1) MX2010004831A (es)
MY (1) MY149546A (es)
NZ (1) NZ584911A (es)
PE (1) PE20090981A1 (es)
PL (1) PL2207808T3 (es)
PT (1) PT2207808E (es)
RU (1) RU2513697C2 (es)
SI (1) SI2207808T1 (es)
TN (1) TN2010000199A1 (es)
TW (1) TWI429656B (es)
WO (1) WO2009056509A1 (es)
ZA (1) ZA201002799B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012004773A1 (en) 2010-07-09 2012-01-12 Universite De Geneve New uses of nogo-a inhibitors and related methods
CA2876284A1 (en) 2012-07-05 2014-01-09 Glaxo Group Limited Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis
KR20180069070A (ko) 2015-11-03 2018-06-22 얀센 바이오테크 인코포레이티드 Tim-3과 특이적으로 결합하는 항체 및 그의 용도
CA3158491A1 (en) 2019-10-24 2021-04-29 Novago Therapeutics Ag Novel anti-nogo-a antibodies
WO2024041450A1 (zh) * 2022-08-22 2024-02-29 舒泰神（北京）生物制药股份有限公司 特异性识别Nogo-A的抗体及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308573D0 (en) 1983-03-29 1983-05-05 British Nuclear Fuels Ltd Filament impregnating/coating
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
UA34415C2 (uk) 1989-02-13 2001-03-15 Шерінг Аг Берлін Унд Бергкамен Істотно чистий білок, що є тромболітиком, виділена днк, що його кодує, культура яйцеклітин xenopus laevis, трансформованих вектором, спосіб одержання активатора плазміногена, лікарський тромболітичний засіб
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
CZ304224B6 (cs) * 1998-11-06 2014-01-15 Schwab Monoklonální protilátka
CN1234730C (zh) * 2001-12-30 2006-01-04 上海中科伍佰豪生物工程有限公司 鼠抗氯霉素单克隆抗体及其用途
US7531178B2 (en) 2002-06-07 2009-05-12 Trigen Gmbh Immunoadhesin comprising a glycoprotein VI domain
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
JP5087274B2 (ja) 2003-06-30 2012-12-05 ドマンティス リミテッド ポリペプチド
GB0321997D0 (en) 2003-09-19 2003-10-22 Novartis Ag Organic compound
GB0329684D0 (en) * 2003-12-22 2004-01-28 Glaxo Group Ltd Method
AU2004303585B2 (en) 2003-12-22 2010-12-23 Glaxo Group Limited NOGO-a neutralising immunoglobulins for treatment of neurological diseases
JP4088655B2 (ja) 2004-09-06 2008-05-21 キリンファーマ株式会社 抗ａ３３抗体
WO2007003421A2 (en) 2005-07-05 2007-01-11 Glaxo Group Limited Humanised antibodies specific for nogo-a and pharmaceutical uses thereof
GB0525662D0 (en) * 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
TW200821386A (en) 2006-07-18 2008-05-16 Centocor Inc Human GLP-1 mimetibodies, compositions, methods and uses
CL2008003241A1 (es) 2007-11-02 2009-07-31 Novartis Ag Molecula de enlace que comprende una porcion de enlace de antigeno que se enlaza con un neoepitopo de c3b; composicion farmaceutica que la comprende; y su uso para tratar trastornos oculares
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
KR101039751B1 (ko) 2008-10-16 2011-06-09 한국생명공학연구원 Ｔｍｐｒｓｓ４―특이적인 인간항체

Also Published As

Publication number Publication date
JP5698534B2 (ja) 2015-04-08
WO2009056509A1 (en) 2009-05-07
AU2008317724B2 (en) 2011-06-02
TW200934791A (en) 2009-08-16
IL205357A0 (en) 2010-12-30
US20120171215A1 (en) 2012-07-05
PT2207808E (pt) 2013-08-26
CA2704357C (en) 2016-06-21
CN101910200B (zh) 2013-12-18
MA31805B1 (fr) 2010-10-01
MX2010004831A (es) 2010-05-21
AU2008317724A1 (en) 2009-05-07
BRPI0818928A2 (pt) 2017-05-16
US8163285B2 (en) 2012-04-24
NZ584911A (en) 2011-08-26
US20110027284A1 (en) 2011-02-03
ES2425768T3 (es) 2013-10-17
BRPI0818928B1 (pt) 2021-12-07
IL221723A0 (en) 2012-10-31
HRP20130699T1 (hr) 2013-11-22
TN2010000199A1 (en) 2011-11-11
MY149546A (en) 2013-09-13
CA2704357A1 (en) 2009-05-07
CY1114345T1 (el) 2016-08-31
KR20100100848A (ko) 2010-09-15
HK1143597A1 (en) 2011-01-07
IL205357A (en) 2014-08-31
RU2513697C2 (ru) 2014-04-20
CO6270357A2 (es) 2011-04-20
TWI429656B (zh) 2014-03-11
JO2876B1 (en) 2015-03-15
AR072934A1 (es) 2010-09-29
JP2011502476A (ja) 2011-01-27
EP2207808A1 (en) 2010-07-21
EP2207808B1 (en) 2013-05-08
KR101574814B1 (ko) 2015-12-04
CN101910200A (zh) 2010-12-08
IL221723A (en) 2014-08-31
RU2010122044A (ru) 2011-12-10
ZA201002799B (en) 2011-01-26
PL2207808T3 (pl) 2013-11-29
US8758754B2 (en) 2014-06-24
CL2008003240A1 (es) 2009-06-05
SI2207808T1 (sl) 2013-09-30
DK2207808T3 (da) 2013-08-05

Similar Documents

Publication Publication Date Title
PE20190976A1 (es) Anticuerpos de union a cd3
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
PH12018501554A1 (en) Ror1 antibody compositions and related methods
EA201892362A1 (ru) Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
PE20090329A1 (es) Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
PE20190120A1 (es) Moleculas de union a bcma y metodos de uso de las mismas
PE20131209A1 (es) Anticuerpos anti-fap
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
PH12018502538A1 (en) Antibodies to alpha-synuclein and uses thereof
PE20121552A1 (es) Anticuerpos monoclonales anti cea humanizados de afinidad madura
AR096617A1 (es) Anticuerpos anti-tweakr y sus usos
AR063090A1 (es) Proteinas de union al antigeno del receptor de la il-17
PE20110668A1 (es) Anticuerpos anti-linfopoyetina estromal timica (anti-tslp)
AR063829A1 (es) Moleculas de enlace de lingo y uso farmaceutico de las mismas
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
EA201290570A1 (ru) Конструкты, связывающиеся с ron, и способы их использования
AR091605A1 (es) Proteinas de union anti-mesotelina
CO6251370A2 (es) Una molecula de union cd20 humanizda que comprende un dominio variable de cadena pesada de inmunoglobulina (vh) y un dominio variable de cadena liviana de inmunoglobulina (vl) y metodos de uso de la misma
PE20091193A1 (es) Proteinas humanas de union a antigenos del gm-csf
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
EA201291039A1 (ru) Антитела, связывающие cd27 человека, и их применение
PE20110225A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
DOP2016000282A (es) Anticuerpos humanizados contra la molécula de adhesión celular relacionada al antígeno carcinoembriónico 1 (ceacam1)
MX2016011934A (es) Inmunoglobulina hibrida conteniendo un enlace no-peptidilico.
MX2021000392A (es) Anticuerpos anti-mesotelina.

Legal Events

Date Code Title Description
FG Grant, registration